Press release

DSM marks milestone in authorization of ampli-D® in Europe

Kaiseraugst (CH), 7 Jul 2021

Royal DSM, a global science-based company active in Nutrition, Health and Sustainable Living, has received a positive EFSA opinion for the Novel Food assessment of calcidiol, also known as calcifediol. The recognition of the safety and bioavailability of calcidiol for the intended use is a key milestone in the authorization of DSM’s ampli-D® product for sale across the European Union. EFSA recognized the more efficient absorption of calcidiol compared to regular vitamin D3 to increase the level of vitamin D in the blood and hence improve the vitamin D status of an individual.           

Widely recognized for its role in bone and muscle health as well as for the maintenance of a normal immune system, a growing bank of scientific evidence also shows that vitamin D could reduce the risk of acute respiratory infections. With 65% of global consumers currently concerned about their immune health1, the future inclusion of calcidiol on the Union list of novel foods for use in food supplements will take DSM a step closer to enabling its customers to bring fast-acting vitamin D solutions to market serving various health benefits.

“Consumers increasingly recognize the growing associations between the so-called ‘sunshine vitamin’ and immunity, yet globally 88% of individuals are reported to have sub-optimal vitamin D levels2,” comments Martin Dos Ramos, Vice President Dietary Supplements at DSM. “DSM’s new ampli-D®, a highly bioavailable form of vitamin D3, is ideally placed to support dietary supplement brands in creating purpose-led products that can quickly tackle low vitamin D status – achieving optimal levels in the body in a matter of days and weeks, rather than months.”

André Rhoen, Regional Vice President EMEA at DSM adds: “This positive EFSA opinion opens up exciting potential in vitamin D innovation, with the addition of an advanced and potent form to our portfolio. This important landmark is testament to the role that DSM plays as an end-to-end partner to our customers – from scientific and regulatory services, right through to the market-ready solutions that will be commercially available as soon as we receive authorization from the European Commission.”

The positive EFSA opinion confirms the safe use of calcidiol in food supplements for children above 11 years old and for the adult population including pregnant and lactating women. For more information on ampli-D®, contact us at


  1. DSM Consumer Immunity Panel, September 2020.
  2. Hilger et al. A systematic review of vitamin D status in populations worldwide. Br J Nutr 2014, 111, 23-45.
  3. Clinical studies show that sufficient Vitamin D status is achieved on average 3 times faster and more efficiently compared to D3 on an equal dose basis.

For more information

Emma Couderc-Peyrachon

DSM Human Nutrition & Health
+41 79 562 33 50

Jenny Mason

Barrett Dixon Bell
+44 161 925 4700